Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.
This lecture by dr. Mathias Haarhaus, was part of an accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.
Dr. Mathias Haarhaus, MD, Consultant Nephrologist at the Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Vascular calcification in kidney disease: Epigenetics as a novel approach?Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?
Marta Ruiz-Ortega, PhD
- Vascular calcification in kidney disease: Epigenetics as a novel approach?Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition
Vincent Brandenburg, MD